June 26 (Reuters) - Edgewise Therapeutics Inc EWTX.O:
EDGEWISE THERAPEUTICS REPORTS POSITIVE RESULTS ON SEVASEMTEN PROGRAM FOR BECKER AND DUCHENNE MUSCULAR DYSTROPHIES
EDGEWISE THERAPEUTICS INC - TO MEET WITH FDA IN Q4 2025 TO DISCUSS PHASE 3 DESIGN
EDGEWISE THERAPEUTICS INC - NEW DATA SHOWS SUSTAINED DISEASE STABILIZATION IN BECKER UP TO THREE YEARS
EDGEWISE THERAPEUTICS INC - PHASE 2 OBSERVATIONS IN DUCHENNE DEFINE DOSE FOR PHASE 3
Source text: ID:nPn28zVJka
Further company coverage: EWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.